FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Figlin

Research Profile

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Anatomy

Lymphocytes, Tumor-Infiltrating

Co-author Network

Publications

TOP 3
Sumanta K Pal; Paulo G Bergerot; Robert A Figlin
Tivozanib: current status and future directions in the treatment of solid tumors.
Hai T Tran; Amado J Zurita; Rafael G Amado; Katherine L Baker-Neblett; Robert A Figlin; Thomas E Hutson; Ying Lin; Yuan Liu; Anne-Marie Martin; Lini N Pandite; Cora N Sternberg; John V Heymach
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Robert J Motzer; Mark R Olsen; John A Thompson; Olga Valota; George Wilding; Jinyu Yuan; Neeraj Agarwal; Akintunde Bello; John M Burke; David Cella; William J Edenfield; Subramanian Hariharan; Gary R Hudes; Thomas E Hutson; Beata Korytowsky; Bridget Martell; Robert A Figlin
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Figlin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Sumanta K Pal; Paulo G Bergerot; Robert A Figlin
Tivozanib: current status and future directions in the treatment of solid tumors.
Expert opinion on investigational drugs 2012;21(12):1851-9.
2012: Hai T Tran; Amado J Zurita; Rafael G Amado; Katherine L Baker-Neblett; Robert A Figlin; Thomas E Hutson; Ying Lin; Yuan Liu; Anne-Marie Martin; Lini N Pandite; Cora N Sternberg; John V Heymach
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
The lancet oncology 2012;13(8):827-37.
2012: Robert J Motzer; Mark R Olsen; John A Thompson; Olga Valota; George Wilding; Jinyu Yuan; Neeraj Agarwal; Akintunde Bello; John M Burke; David Cella; William J Edenfield; Subramanian Hariharan; Gary R Hudes; Thomas E Hutson; Beata Korytowsky; Bridget Martell; Robert A Figlin
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(12):1371-7.
2012: Xiwei Wu; Jeffrey J Wu; Maricela Covarrubias; Robert A Figlin; Hanlin Gao; Chao Guo; Jennifer M Jin; Xuejun Li; Yuping Li; Bing Mu; Rebecca A Nelson; Susan H Onami; Sumanta K Pal; Nora H Ruel; Lawrence M Weiss; Lihong Weng; Sharon P Wilczynski; Huiqing Wu
Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis.
PloS one 2012;7(5):e35661.
2011: Sumanta Kumar Pal; Robert A Figlin
Unraveling the role of hypoxia-inducible factor in renal cell carcinoma: a biological and therapeutic perspective.
Cancer discovery 2011;1(3):198-9.
2011: Sumanta K Pal; Ari VanderWalde; Arti Hurria; Robert A Figlin
Systemic therapies for metastatic renal cell carcinoma in older adults.
Drugs & aging 2011;28(8):635-49.
2011: Sumanta Kumar Pal; Robert A Figlin
Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
Targeted oncology 2011;6(1):5-16.
2011: Sujata M Patil; Robert A Figlin; T E Hutson; M Dror Michaelson; S Négrier; S T Kim; X Huang; Robert J Motzer
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(2):295-300.
2010: Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.
Molecular cancer therapeutics 2010;9(12):3115-25.
2010: Sumanta Kumar Pal; Karen Reckamp; Hua Yu; Robert A Figlin
Akt inhibitors in clinical development for the treatment of cancer.
Expert opinion on investigational drugs 2010;19(11):1355-66.
2010: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Andrea Kay; Alain Ravaud
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.
Cancer 2010;116(18):4256-65.
2010: Sumanta Kumar Pal; Robert A Figlin
Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape.
Nature reviews. Clinical oncology 2010;7(7):362-3.
2010: Sumanta Kumar Pal; Robert A Figlin; Karen Reckamp
Targeted therapies for non-small cell lung cancer: an evolving landscape.
Molecular cancer therapeutics 2010;9(7):1931-44.
2010: Sumanta Kumar Pal; Robert A Figlin
Targeted therapies for renal cell carcinoma: understanding their impact on survival.
Targeted oncology 2010;5(2):131-8.
2010: Sumanta Kumar Pal; Robert A Figlin
Renal cell carcinoma therapy in 2010: many options with little comparative data.
Clinical advances in hematology & oncology : H&O 2010;8(3):191-200.
2010: Sumanta Kumar Pal; Robert A Figlin
Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.
Clinical Medicine Insights. Oncology 2010;4():43-53.
2009: Robert A Figlin
Anti-angiogenic therapy in renal cell carcinoma: Alone, in combination, or sequentially.
Clinical advances in hematology & oncology : H&O 2009;7(10):662-5.
2009: Robert A Figlin; Paul de Souza; David McDermott; Janice P Dutcher; Anna Berkenblit; Alexandra Thiele; Mizue Krygowski; Andrew Strahs; Jay Feingold; Joseph Boni; Gary Hudes
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Cancer 2009;115(16):3651-60.
2009: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia del Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(22):3584-90.
2009: Karen Reckamp; Robert A Figlin; Marie D Burdick; Steven M Dubinett; Robert M Elashoff; Robert M Strieter
CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.
BMC cancer 2009;9():213.
2009: Robert J Motzer; Gary Hudes; George Wilding; Lawrence H Schwartz; Subramanian Hariharan; Susan Kempin; Rana Fayyad; Robert A Figlin
Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.
Clinical genitourinary cancer 2009;7(1):28-33.
2008: Thomas E Hutson; Robert A Figlin
Experimental therapy for advanced renal cell carcinoma.
Expert opinion on investigational drugs 2008;17(11):1693-702.
2008: Thomas E Hutson; Robert A Figlin; John Kuhn; Robert J Motzer
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
The oncologist 2008;13(10):1084-96.
2008: Robert J Motzer; Ronald M Bukowski; Robert A Figlin; Thomas E Hutson; M Dror Michaelson; Sindy T Kim; Charles M Baum; Michael W Kattan
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
Cancer 2008;113(7):1552-8.
2008: Robert A Figlin
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Nature clinical practice. Oncology 2008;5(10):601-9.
2008: Robert A Figlin; Elizabeth Brown; Andrew J Armstrong; Wallace Akerley; Al B Benson; Harold J Burstein; David S Ettinger; Phillip G Febbo; Matthew G Fury; Gary R Hudes; Merrill S Kies; Eunice L Kwak; Robert J Morgan; Joanne Mortimer; Karen Reckamp; Alan P Venook; Frank Worden; Yun Yen
NCCN Task Force Report: mTOR inhibition in solid tumors.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6 Suppl 5():S1-20; quiz S21-2.
2008: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet 2008;372(9637):449-56.
2008: Przemyslaw Twardowski; Robert A Figlin
Bevacizumab plus interferon alpha in patients with metastatic renal cell carcinoma.
Nature clinical practice. Oncology 2008;5(8):436-7.
2008: Eric Jonasch; Walter M Stadler; Ronald M Bukowski; Teresa G Hayes; Atul Varadhachary; Rajesh Malik; Robert A Figlin; Sandy Srinivas
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
Cancer 2008;113(1):72-7.
2008: Karen Reckamp; Robert M Strieter; Robert A Figlin
Chemokines as therapeutic targets in renal cell carcinoma.
Expert review of anticancer therapy 2008;8(6):887-93.
2008: David S Ettinger; Wallace Akerley; Gerold Bepler; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Steven Feigenberg; Robert A Figlin; Ramaswamy Govindan; Frederic W Grannis; Thierry jahan; Mohammad Jahanzeb; Anne Kessinger; Ritsuko Komaki; Mark G Kris; Corey J Langer; Quynh-Thu Le; Renato Martins; Gregory A Otterson; Jyoti D Patel; Francisco Robert; David J Sugarbaker; Douglas E Wood
Non-small cell lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(3):228-69.
2008: John S Lam; Tobias Klatte; Hyung L Kim; Jean-Jacques Patard; Alberto Breda; Amnon Zisman; Allan J Pantuck; Robert A Figlin
Prognostic factors and selection for clinical studies of patients with kidney cancer.
Critical reviews in oncology/hematology 2008;65(3):235-62.
2008: Karen Reckamp; Brian Gardner; Robert A Figlin; David Elashoff; Kostyantyn Krysan; Mariam Dohadwala; Jenny Mao; Sherven Sharma; Landon Inge; Ayyappan Rajasekaran; Steven M Dubinett
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(2):117-24.
2007: Robert A Figlin
Temsirolimus for advanced renal cell carcinoma.
Clinical advances in hematology & oncology : H&O 2007;5(11):893.
2007: Tobias Klatte; Jean-Jacques Patard; Rakhee H Goel; Mark D Kleid; Francois Guille; Bernard Lobel; Claude C Abbou; Alexandre de la Taille; Jacques Tostain; Luca Cindolo; Vincenzo Altieri; Vincenzo Ficarra; Walter Artibani; Tommaso Prayer-Galetti; Ernst Peter Allhoff; Luigi Schips; Richard Zigeuner; Robert A Figlin; Fairooz Kabbinavar; Allan J Pantuck; Arie S Belldegrun; John S Lam
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience.
The Journal of urology 2007;178(1):35-40; discussion 40.
2007: John S Lam; Tobias Klatte; Jean-Jacques Patard; Rakhee H Goel; François Guillè; Bernard Lobel; Claude C Abbou; Alexandre de la Taille; Jacques Tostain; Luca Cindolo; Vincenzo Altieri; Vincenzo Ficarra; Walter Artibani; Tommaso Prayer-Galetti; Luigi Schips; Richard Zigeuner; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience.
European urology 2007;52(1):155-62.
2007: Allan J Pantuck; David Seligson; Tobias Klatte; Hong Yu; John T Leppert; Laurence Moore; Timothy O'Toole; Jay Gibbons; Arie S Belldegrun; Robert A Figlin
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Cancer 2007;109(11):2257-67.
2007: Karen Reckamp; Robert A Figlin; Nancy Moldawer; Allan J Pantuck; Arie S Belldegrun; Marie D Burdick; Robert M Strieter
Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2007;30(4):417-24.
2007: John T Leppert; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
The role of molecular markers in the staging of renal cell carcinoma.
BJU international 2007;99(5 Pt B):1208-11.
2007: Tobias Klatte; Jinsoo Chung; John T Leppert; John S Lam; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma.
BJU international 2007;99(4):821-4.
2007: John S Lam; Allan J Pantuck; Arie S Belldegrun; Robert A Figlin
Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 2):703s-708s.
2006: John S Lam; Alberto Breda; Arie S Belldegrun; Robert A Figlin
Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(35):5565-75.
2006: Y C Yang; Ming-Lan Lu; Jian Yu Rao; H Wallerand; Lin Cai; Wei Cao; Allan J Pantuck; Guido Dalbagni; Victor E Reuter; Robert A Figlin; Arie Belldegrun; Carlos Cordon-Cardo; Zuo-Feng Zhang
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.
British journal of cancer 2006;95(11):1455-8.
2006: Oleg Shvarts; Nicolette K Janzen; John S Lam; John T Leppert; Randy Caliliw; Robert A Figlin; Arie S Belldegrun; Gang Zeng
RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma.
Urology 2006;68(5):1132-8.
2006: Allan J Pantuck; George Thomas; Arie S Belldegrun; Robert A Figlin
Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
Seminars in oncology 2006;33(5):607-13.
2006: Brian M Shuch; John S Lam; Arie S Belldegrun; Robert A Figlin
Prognostic factors in renal cell carcinoma.
Seminars in oncology 2006;33(5):563-75.
2006: Karen Reckamp; Kostyantyn Krysan; Jason D Morrow; Ginger L Milne; Robert A Newman; Christopher Tucker; Robert M Elashoff; Steven M Dubinett; Robert A Figlin
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3381-8.
2006: John S Lam; Arie S Belldegrun; Robert A Figlin
Adjuvant treatment for renal cell carcinoma.
Expert opinion on pharmacotherapy 2006;7(6):705-20.
2005: Wei Cao; Lin Cai; Jian Yu Rao; Allan J Pantuck; Ming-Lan Lu; Guido Dalbagni; Victor E Reuter; Howard I Scher; Carlos Cordon-Cardo; Robert A Figlin; Arie Belldegrun; Zuo-Feng Zhang
Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma.
Cancer 2005;104(11):2400-8.
2005: John S Lam; John T Leppert; Robert A Figlin; Arie S Belldegrun
Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.
Urology 2005;66(5 Suppl):1-9.
2005: Javier Mestas; Marie D Burdick; Karen Reckamp; Allan J Pantuck; Robert A Figlin; Robert M Strieter
The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(8):5351-7.
2005: John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options.
BJU international 2005;96(4):483-8.
2005: John T Leppert; John S Lam; Allan J Pantuck; Robert A Figlin; Arie S Belldegrun
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.
BJU international 2005;96(3):281-5.
2005: John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Novel approaches in the therapy of metastatic renal cell carcinoma.
World journal of urology 2005;23(3):202-12.
2005: John S Lam; Oleg Shvarts; Jonathan W Said; Allan J Pantuck; David Seligson; Michael E Aldridge; Matthew H T Bui; Xueli Liu; Steve Horvath; Robert A Figlin; Arie S Belldegrun
Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
Cancer 2005;103(12):2517-25.
2005: John S Lam; Oleg Shvarts; John T Leppert; Robert A Figlin; Arie S Belldegrun
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
The Journal of urology 2005;173(6):1853-62.
2005: Hyung L Kim; David Seligson; Xueli Liu; Nicolette K Janzen; Matthew H T Bui; Hong Yu; Tao Shi; Arie S Belldegrun; Steve Horvath; Robert A Figlin
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.
The Journal of urology 2005;173(5):1496-501.
2005: John S Lam; Allan J Pantuck; Arie S Belldegrun; Robert A Figlin
G250: a carbonic anhydrase IX monoclonal antibody.
Current oncology reports 2005;7(2):109-15.
2005: John S Lam; John T Leppert; Robert A Figlin; Arie S Belldegrun
Surveillance following radical or partial nephrectomy for renal cell carcinoma.
Current urology reports 2005;6(1):7-18.
2004: John S Lam; Arie S Belldegrun; Robert A Figlin
Advances in immune-based therapies of renal cell carcinoma.
Expert review of anticancer therapy 2004;4(6):1081-96.
2004: John S Lam; Arie S Belldegrun; Robert A Figlin
Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 2):6304S-9S.
2004: Ken-Ryu Han; Nicolette K Janzen; Valerie C McWhorter; Hyung L Kim; Allan J Pantuck; Amnon Zisman; Robert A Figlin; Frederick J Dorey; Jonathan W Said; Arie S Belldegrun
Cystic renal cell carcinoma: biology and clinical behavior.
Urologic oncology 2004;22(5):410-4.
2004: Robert A Figlin; H Alvin; C L Meinhardt
Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.
Der Urologe. Ausg. A 2004;43 Suppl 3():S144-5.
2004: Hyung L Kim; David Seligson; Xueli Liu; Nicolette K Janzen; Matthew H T Bui; Hong Yu; Tao Shi; Robert A Figlin; Steve Horvath; Arie S Belldegrun
Using protein expressions to predict survival in clear cell renal carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5464-71.
2004: Matthew H T Bui; Harri Visapaa; David Seligson; Hyung Kim; Ken-Ryu Han; Yunda Huang; Steve Horvath; Eric J Stanbridge; Aarno Palotie; Robert A Figlin; Arie S Belldegrun
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma.
The Journal of urology 2004;171(6 Pt 1):2461-6.
2004: Jean-Jacques Patard; Oleg Shvarts; John S Lam; Allan J Pantuck; Hyung L Kim; Vincenzo Ficarra; Luca Cindolo; Ken-Ryu Han; Alexandre de la Taille; Jacques Tostain; Walter Artibani; Claude C Abbou; Bernard Lobel; Dominique K Chopin; Robert A Figlin; Peter F A Mulders; Arie S Belldegrun
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience.
The Journal of urology 2004;171(6 Pt 1):2181-5, quiz 2435.
2004: Ken-Ryu Han; Hyung L Kim; Allan J Pantuck; Frederick J Dorey; Robert A Figlin; Arie S Belldegrun
Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma.
Urology 2004;63(5):841-6; discussion 846-7.
2004: Robert D Suh; Jonathan G Goldin; Amanda B Wallace; Ramon E Sheehan; Stefan B Heinze; Barbara J Gitlitz; Robert A Figlin
Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
Radiology 2004;231(2):359-64.
2004: Hyung L Kim; Ken-Ryu Han; Amnon Zisman; Robert A Figlin; Arie S Belldegrun
Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma.
The Journal of urology 2004;171(5):1810-3.
2004: Allan J Pantuck; Arndt van Ophoven; Barbara J Gitlitz; Cho-Lea Tso; Bruce Acres; Patrick Squiban; Michael E Ross; Arie S Belldegrun; Robert A Figlin
Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(3):240-53.
2004: David Seligson; Allan J Pantuck; Xueli Liu; Yunda Huang; Steve Horvath; Matthew H T Bui; Ken-Ryu Han; Adrian J L Correa; Mervi Eeva; Sheila Tze; Arie S Belldegrun; Robert A Figlin
Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(8):2659-69.
2004: Hideki Mukouyama; Nicolette K Janzen; Jose M Hernandez; John S Lam; Randy Caliliw; Allen Y Wang; Robert A Figlin; Arie S Belldegrun; Gang Zeng
Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1421-9.
2004: Hyung L Kim; Amnon Zisman; Ken-Ryu Han; Robert A Figlin; Arie S Belldegrun
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?
The Journal of urology 2004;171(2 Pt 1):588-91.
2003: Bradley C Leibovich; Ken-Ryu Han; Matthew H T Bui; Allan J Pantuck; Frederick J Dorey; Robert A Figlin; Arie Belldegrun
Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Cancer 2003;98(12):2566-75.
2003: Ken-Ryu Han; Ivar Bleumer; Allan J Pantuck; Hyung L Kim; Frederick J Dorey; Nicolette K Janzen; Amnon Zisman; Colin P N Dinney; Christopher G Wood; David A Swanson; Jonathan W Said; Robert A Figlin; Peter F A Mulders; Arie S Belldegrun
Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population.
The Journal of urology 2003;170(6 Pt 1):2221-4.
2003: Nicolette K Janzen; Hyung L Kim; Robert A Figlin; Arie S Belldegrun
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.
The Urologic clinics of North America 2003;30(4):843-52.
2003: Barbara J Gitlitz; Carole Baker; Yvonne Chapman; Heather J Allen; Linda D Bosserman; Ravi Patel; James D Sanchez; Richard M Shapiro; Robert A Figlin
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Cancer 2003;98(9):1863-9.
2003: Hyung L Kim; Arie S Belldegrun; Danielo G Freitas; Matthew H T Bui; Ken-Ryu Han; Frederick J Dorey; Robert A Figlin
Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis.
The Journal of urology 2003;170(5):1742-6.
2003: Sylvia M Kiertscher; Barbara J Gitlitz; Robert A Figlin; Michael D Roth
Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients.
International journal of cancer. Journal international du cancer 2003;107(2):256-61.
2003: Allan J Pantuck; Gang Zeng; Arie S Belldegrun; Robert A Figlin
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4641-52.
2003: Barbara J Gitlitz; Arie S Belldegrun; Amnon Zisman; Debby H Chao; Allan J Pantuck; Andreas Hinkel; Peter F A Mulders; Nancy Moldawer; Cho-Lea Tso; Robert A Figlin
A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(5):412-9.
2003: Ganesh S Palapattu; Allan J Pantuck; Frederick Dorey; Jonathan W Said; Robert A Figlin; Arie S Belldegrun
Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies.
The Journal of urology 2003;170(3):768-72; discussion 772.
2003: Barbara J Gitlitz; Robert A Figlin
Cytokine-based therapy for metastatic renal cell cancer.
The Urologic clinics of North America 2003;30(3):589-600.
2003: Allan J Pantuck; Amnon Zisman; Frederick Dorey; Debby H Chao; Ken-Ryu Han; Jonathan Said; Barbara J Gitlitz; Arie S Belldegrun; Robert A Figlin
Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
Cancer 2003;97(12):2995-3002.
2003: Allan J Pantuck; Amnon Zisman; Frederick Dorey; Debby H Chao; Ken-Ryu Han; Jonathan Said; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
The Journal of urology 2003;169(6):2076-83.
2003: José M Hernández; Matthew H T Bui; Ken-Ryu Han; Hideki Mukouyama; Danielo G Freitas; David Nguyen; Randy Caliliw; Peter Shintaku; Sun H Paik; Cho-Lea Tso; Robert A Figlin; Arie S Belldegrun
Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1906-16.
2003: Barbara J Gitlitz; Robert A Figlin; Sylvia M Kiertscher; Nancy Moldawer; Frances Rosen; Michael D Roth
Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(2):171-8.
2003: Amnon Zisman; Jeff A Wieder; Allan J Pantuck; Debby H Chao; Frederick Dorey; Jonathan W Said; Barbara J Gitlitz; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.
The Journal of urology 2003;169(3):909-16.
2003: Ken-Ryu Han; Matthew H T Bui; Allan J Pantuck; Danielo G Freitas; Bradley C Leibovich; Frederick J Dorey; Amnon Zisman; Nicolette K Janzen; Hideki Mukouyama; Robert A Figlin; Aie S Belldegrun
TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion.
The Journal of urology 2003;169(3):899-903; discussion 903-4.
2003: Ken-Ryu Han; Allan J Pantuck; Matthew H T Bui; Oleg Shvarts; Danielo G Freitas; Amnon Zisman; Bradley C Leibovich; Frederick J Dorey; Barbara J Gitlitz; Robert A Figlin; Arie S Belldegrun
Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.
Urology 2003;61(2):314-9.
2003: Hyung L Kim; Arie S Belldegrun; Robert A Figlin
Immune gene therapy for kidney cancer: the search for a magic trigger.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(2):153-4.
2003: Matthew H T Bui; David Seligson; Ken-Ryu Han; Allan J Pantuck; Frederick J Dorey; Yunda Huang; Steve Horvath; Bradley C Leibovich; Shefali Chopra; Shu-Yuan Liao; Eric J Stanbridge; Michael I Lerman; Aarno Palotie; Robert A Figlin; Arie S Belldegrun
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):802-11.
2002: Amnon Zisman; Allan J Pantuck; Jeffery Wieder; Debby H Chao; Frederick Dorey; Jonathan W Said; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4559-66.
2002: Amnon Zisman; Debby H Chao; Allan J Pantuck; Hyun J Kim; Jeff A Wieder; Robert A Figlin; Jonathan W Said; Arie S Belldegrun
Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype.
The Journal of urology 2002;168(3):950-5.
2002: Amnon Zisman; Allan J Pantuck; Frederick Dorey; Debby H Chao; Barbara J Gitlitz; Nancy Moldawer; Dana Lazarovici; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Mathematical model to predict individual survival for patients with renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1368-74.
2001: Amnon Zisman; Allan J Pantuck; D Chao; Frederick Dorey; Jonathan W Said; Barbara J Gitlitz; Jean B De Kernion; Robert A Figlin; Arie S Belldegrun
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.
The Journal of urology 2001;166(1):54-8.
2001: Barbara J Gitlitz; A S Belldegrun; Robert A Figlin
Vaccine and gene therapy of renal cell carcinoma.
Seminars in urologic oncology 2001;19(2):141-7.
2001: Amnon Zisman; Allan J Pantuck; Frederick Dorey; Jonathan W Said; Oleg Shvarts; D Quintana; Barbara J Gitlitz; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Improved prognostication of renal cell carcinoma using an integrated staging system.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1649-57.
2001: Barbara J Gitlitz; DM Hoffman; Nancy Moldawer; Arie Belldegrun; Robert A Figlin
Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients.
Cancer journal (Sudbury, Mass.) 2001;7(2):112-20.
2001: Barbara J Gitlitz; Robert A Figlin; Allan J Pantuck; Arie S Belldegrun
Dendritic cell-based immunotherapy of renal cell carcinoma.
Current urology reports 2001;2(1):46-52.
2000: DM Hoffman; Robert A Figlin
Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex.
World journal of urology 2000;18(2):152-6.
2000: DM Hoffman; Barbara J Gitlitz; Arie Belldegrun; Robert A Figlin
Adoptive cellular therapy.
Seminars in oncology 2000;27(2):221-33.
2000: Michael D Roth; Barbara J Gitlitz; Sylvia M Kiertscher; AN Park; M Mendenhall; Nancy Moldawer; Robert A Figlin
Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients.
Cancer research 2000;60(7):1934-41.
2000: Ke-hung Tsui; Oleg Shvarts; Robert B Smith; Robert A Figlin; Jean B deKernion; Arie Belldegrun
Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.
The Journal of urology 2000;163(4):1090-5; quiz 1295.
1999: Robert A Figlin; J A Thompson; R M Bukowski; N J Vogelzang; A C Novick; P Lange; G D Steinberg; Arie S Belldegrun
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2521-9.
1999: Robert A Figlin
Renal cell carcinoma: management of advanced disease.
The Journal of urology 1999;161(2):381-6; discussion 386-7.
1997: Robert A Figlin; W C Pierce; R Kaboo; Cho-Lea Tso; Nancy Moldawer; Barbara J Gitlitz; Jean B deKernion; Arie Belldegrun
Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
The Journal of urology 1997;158(3 Pt 1):740-5.
1997: Mark S Litwin; J T Fine; Frederick Dorey; Robert A Figlin; Arie S Belldegrun
Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.
The Journal of urology 1997;157(5):1608-12.
1996: Mitchell H Sokoloff; Cho-Lea Tso; R Kaboo; S Nelson; J Ko; Frederick Dorey; Robert A Figlin; Shen Pang; Jean B deKernion; A Belldegrun
Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients.
The Journal of urology 1996;156(5):1560-6.
1996: Mitchell H Sokoloff; Jean B deKernion; Robert A Figlin; A Belldegrun
Current management of renal cell carcinoma.
CA: a cancer journal for clinicians 1996;46(5):284-302.
1996: Robert A Figlin; J J Crowley; E L Jacobs; M Muirhead; J W Goodwin; J J Rinehart; R B Livingston
Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Cancer 1996;78(5):998-1003.
1996: Denise R Aberle; John David N Dionisio; Michael F McNitt-Gray; Ricky K Taira; A F Cárdenas; Jonathan G Goldin; K Brown; Robert A Figlin; Wesley W Chu
Integrated multimedia timeline of medical images and data for thoracic oncology patients.
Radiographics : a review publication of the Radiological Society of North America, Inc 1996;16(3):669-81.
1996: John K Fraser; Michael Lill; Robert A Figlin
The biology of the cytokine sequence cascade.
Seminars in oncology 1996;23(2 Suppl 4):2-8.
1995: J D Lee; S Perez; H J Wang; Robert A Figlin; Carmack Holmes
Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience.
Journal of surgical oncology 1995;60(4):262-7.
1995: W C Pierce; A Belldegrun; Robert A Figlin
Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
Seminars in oncology 1995;22(1):74-80.
1993: Robert A Figlin; W C Pierce; A Belldegrun
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Seminars in oncology 1993;20(6 Suppl 9):11-5.
1993: A Belldegrun; W Pierce; D Sayah; Jean B deKernion; David Wallach; D Aderka; Robert A Figlin
Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):175-80.
1993: W C Pierce; Robert A Figlin
Primary tumors of the lung other than lung cancer.
Current opinion in oncology 1993;5(2):343-52.
1992: B Hofmann; H Bass; P Nishanian; M Faisal; Robert A Figlin; G P Sarna; John L Fahey
Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
Clinical and experimental immunology 1992;88(3):548-54.
1992: Robert A Figlin
Cancer immunotherapy using tumor-infiltrating lymphocytes.
Seminars in hematology 1992;29(2 Suppl 1):33-5.
1992: Robert A Figlin; A Belldegrun; Nancy Moldawer; J Zeffren; Jean B deKernion
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(3):414-21.
1991: E L Jacobs; Michael J Clare-Salzler; I J Chopra; Robert A Figlin
Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(6):448-55.
1991: A Belldegrun; A S Abi-Aad; Robert A Figlin; Jean B deKernion
Renal cell carcinoma: basic biology and current approaches to therapy.
Seminars in oncology 1991;18(5 Suppl 7):96-101.
1991: Robert A Figlin; A S Abi-Aad; A Belldegrun; Jean B deKernion
The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.
Seminars in oncology 1991;18(5 Suppl 7):102-7.
1991: A S Abi-Aad; Robert A Figlin; A Belldegrun; Jean B deKernion
Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(4):292-5.
1991: H J Ross; L A Moy; R Kaplan; Robert A Figlin
Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatment.
Cancer 1991;68(2):441-3.
1991: Joel E Fishman; Denise R Aberle; Nancy Moldawer; A Belldegrun; Robert A Figlin
Atypical contrast reactions associated with systemic interleukin-2 therapy.
AJR. American journal of roentgenology 1991;156(4):833-4.
1989: P A Robertson; H J Ross; Robert A Figlin
Tumor necrosis factor induces hemorrhagic necrosis of a sarcoma.
Annals of internal medicine 1989;111(8):682-4.
1989: Robert A Figlin
Biotherapy in clinical practice.
Seminars in hematology 1989;26(3 Suppl 3):15-24.
1989: G P Sarna; Robert A Figlin; M Pertcheck; B Altrock; S A Kradjian
Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results.
Journal of biological response modifiers 1989;8(1):16-24.
1988: Robert A Figlin
Biotherapy with interferon--1988.
Seminars in oncology 1988;15(6 Suppl 6):3-9.
1988: Otoniel Martínez-Maza; Robert A Figlin; Janis V Giorgi; John L Fahey
Selective decrease in Leu8-negative T cell subpopulations following treatment with recombinant interferon-alpha 2a (rIFN-alpha 2a).
Cellular immunology 1988;117(1):89-98.
1988: Robert A Figlin; Jean B deKernion; E Mukamel; A V Palleroni; L M Itri; G P Sarna
Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(10):1604-10.
1988: Robert A Figlin; L M Itri
Anti-interferon antibodies: a perspective.
Seminars in hematology 1988;25(3 Suppl 3):9-15.
1987: G P Sarna; Robert A Figlin; M Pertcheck
Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanoma.
Journal of biological response modifiers 1987;6(4):375-8.
1987: R A Lindemann; J A Jenkins; Robert A Figlin; S H Golub
Application of a new method for detecting the phenotype of target binding cells.
Cancer immunology, immunotherapy : CII 1987;25(2):153-5.
1985: G P Sarna; Robert A Figlin
Phase II trial of alpha-lymphoblastoid interferon given weekly as treatment of advanced breast cancer.
Cancer treatment reports 1985;69(5):547-9.